Pfizer Begins COVID Pill Study in High-Risk Children Aged 6-17
Pfizer said on Wednesday it has begun a mid-to-late-stage study of its antiviral COVID-19 pill for non-hospitalized children aged 6-17 years who are at high risk of developing severe illness.
Reuters Health Information
source https://www.medscape.com/viewarticle/969986?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/969986?src=rss
Comments
Post a Comment